CNR1 and glioma: Glioma cells express endocannabinoid-sensing GPCRs (type-1 cannabinoid receptor, CB1R; and type-2 cannabinoid receptor, CB2R), which are pharmacologically activated to target various cancer hallmarks, including angiogenesis, proliferation, resistance to programmed cell death, invasiveness, and metastasis (Dumitru et al., 2018; Ellert-Miklaszewska et al., 2020).